Stockscreener 앱 받기
1.36
2.86%
-0.04
시간 외 거래:
1.37
0.01
+0.74%
전일 마감가:
$1.40
열려 있는:
$1.37
하루 거래량:
2.40M
Relative Volume:
0.74
시가총액:
$364.32M
수익:
$236.20M
순이익/손실:
$-5.35M
주가수익비율:
-75.98
EPS:
-0.0179
순현금흐름:
$67.70M
1주 성능:
-8.72%
1개월 성능:
+9.68%
6개월 성능:
-50.90%
1년 성능:
-33.33%
1일 변동 폭
$1.33
$1.40
1주일 범위
$1.33
$1.515
52주 변동 폭
$1.14
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.36 | 375.03M | 236.20M | -5.35M | 67.70M | -0.0179 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.42B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.64B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 44.33B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.51B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 22.84B | 3.18B | 1.33B | 1.04B | 27.90 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | H.C. Wainwright | Buy |
| 2025-04-28 | 개시 | Leerink Partners | Outperform |
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
Is the options market predicting a spike in Akebia Therapeutics stock? - MSN
Downgrade Watch: Should I invest in Akebia Therapeutics Inc before earnings2026 Performance Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Akebia Therapeutics, Inc. v. FibroGen, Inc. - Law.com
Trend Report: What is the earnings history of Akebia Therapeutics IncRecession Risk & Real-Time Buy Zone Alerts - baoquankhu1.vn
AKBA SEC FilingsAkebia Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 - The Manila Times
Is the Options Market Signaling a Surge in Akebia Therapeutics Shares? - Bitget
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock? - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Akebia Q2 2025 Earnings Preview - MSN
AKBA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus
Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase - MSN
Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference - MarketBeat
Akebia Therapeutics Earnings Call: Vafseo Drives Growth - The Globe and Mail
Akebia at Leerink Conference: Strategic Focus on Vafseo and Pipeline By Investing.com - Investing.com Canada
Akebia Therapeutics expands portfolio beyond anemia with new rare kidney disease pipeline centered on AKB-097 and praliciguat - MSN
How The Akebia Therapeutics (AKBA) Story Is Shifting As Vafseo Revenue Assumptions Reset - Yahoo Finance
Akebia tops Q4 revenue expectations as Vafseo momentum strengthens outlook - MSN
Piper Sandler lowers Akebia Therapeutics (AKBA) PT to $4 as firm updates estimates following year-end reports - MSN
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion - MSN
Akebia Therapeutics (NASDAQ:AKBA) CEO John Butler Purchases 69,270 Shares - MarketBeat
Layoff Watch: Does Akebia Therapeutics Inc offer margin of safety2025 Fundamental Recap & Safe Entry Zone Tips - baoquankhu1.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Citigroup Inc. Has $5.23 Million Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference - The Globe and Mail
Akebia Therapeutics CEO to speak at Miami Leerink 2026 healthcare forum - Stock Titan
Akebia Therapeutics Reports Inducement Grants - National Today
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail
Akebia Therapeutics (NASDAQ:AKBA) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat
Wall Street Zen Downgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold - MarketBeat
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: A Potential 233% Upside in the Healthcare Sector - DirectorsTalk Interviews
Akebia Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2025 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics (AKBA) Loss In Q4 2025 Tests Bullish Margin Narratives - simplywall.st
Akebia Therapeutics Inc (AKBA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Akebia Therapeutics, Inc. posts full year 2025 financial results amid commercial and pipeline expansion - Traders Union
Key facts: Akebia Therapeutics reports 47% revenue rise; Phase 2 trials planned - TradingView
Akebia (AKBA) Q4 2025 Earnings Call Transcript - AOL.com
Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Akebia Therapeutics Q4 2025 Earnings Call Insights - Intellectia AI
Akebia Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
AKBA: Vafseo launch drove 50% revenue growth in 2025, with expanding adoption and robust cash reserves - TradingView
Akebia Therapeutics Q4 Earnings Call Highlights - MarketBeat
Akebia Therapeutics Inc (NASDAQ:AKBA) Reports Q4 Revenue Beat and 49% Annual Growth Amid Mixed Market Reaction - ChartMill
Akebia (AKBA) Reports Strong Q4 Revenue and Positive Outlook for Vafseo - GuruFocus
AKEBIA THERAPEUTICS ($AKBA) Releases Q4 2025 Earnings - Quiver Quantitative
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.75%
1.88%
자본화:
|
볼륨(24시간):